odanacatib (BioDeep_00000754376)
代谢物信息卡片
Odanacatib(MK-0822)
化学式: C25H27F4N3O3S (525.170916)
中文名称: 奥当卡替
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(C)(CC(C(=O)NC1(CC1)C#N)NC(C2=CC=C(C=C2)C3=CC=C(C=C3)S(=O)(=O)C)C(F)(F)F)F
InChI: InChI=1S/C25H27F4N3O3S/c1-23(2,26)14-20(22(33)32-24(15-30)12-13-24)31-21(25(27,28)29)18-6-4-16(5-7-18)17-8-10-19(11-9-17)36(3,34)35/h4-11,20-21,31H,12-14H2,1-3H3,(H,32,33)/t20-,21-/m0/s1
描述信息
C78281 - Agent Affecting Musculoskeletal System > C67439 - Bone Resorption Inhibitor
C471 - Enzyme Inhibitor > C783 - Protease Inhibitor
同义名列表
2 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- KEGGdrug: D08955
- PubChem: 10152654
- DrugBank: DB06670
- ChEMBL: CHEMBL481611
- CAS: 603139-19-1
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Stefan Zajic, S Aubrey Stoch, Jacqueline B McCrea, Rose Witter, Ghassan N Fayad, Monika Martinho, Julie A Stone. A phase 1 pooled PK/PD analysis of bone resorption biomarkers for odanacatib, a Cathepsin K inhibitor.
Journal of pharmacokinetics and pharmacodynamics.
2020 10; 47(5):473-484. doi:
10.1007/s10928-020-09699-9. [PMID: 32647957] - Seung Un Seo, Seon Min Woo, Min Wook Kim, Hyun-Shik Lee, Sang Hyun Kim, Sun Chul Kang, Eun-Woo Lee, Kyoung-Jin Min, Taeg Kyu Kwon. Cathepsin K inhibition-induced mitochondrial ROS enhances sensitivity of cancer cells to anti-cancer drugs through USP27x-mediated Bim protein stabilization.
Redox biology.
2020 02; 30(?):101422. doi:
10.1016/j.redox.2019.101422. [PMID: 31901727] - Julie A Stone, Jacqueline B McCrea, Rose Witter, Stefan Zajic, S Aubrey Stoch. Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis.
British journal of clinical pharmacology.
2019 06; 85(6):1072-1083. doi:
10.1111/bcp.13869. [PMID: 30663085] - Dinisha Cyril Pirapaharan, Kent Søe, Preety Panwar, Jonna Skov Madsen, Marianne Lerbæk Bergmann, Martin Overgaard, Dieter Brömme, Jean-Marie Delaisse. A Mild Inhibition of Cathepsin K Paradoxically Stimulates the Resorptive Activity of Osteoclasts in Culture.
Calcified tissue international.
2019 01; 104(1):92-101. doi:
10.1007/s00223-018-0472-7. [PMID: 30194476] - Xia Chen, Ji Jiang, Pei Hu, Stefan Zajic, Wen Liu, Jacqueline McCrea, Fang Liu, Rose Witter, Eric Mangin, S Aubrey Stoch. Odanacatib Pharmacokinetics Comparison Between Chinese and Non-Chinese Postmenopausal Women.
Clinical pharmacology in drug development.
2018 09; 7(7):744-750. doi:
10.1002/cpdd.434. [PMID: 29443463] - Bennett Ma, Bin Luo, Danielle H Euler, Tara E Cusick, Gregg Wesolowski, Helmut Glantschnig, Le T Duong, Yangsi Ou, Steven S Carroll, Laura S Lubbers. Applicability of in vitro-in vivo translation of cathepsin K inhibition from animal species to human with the use of free-drug hypothesis.
Naunyn-Schmiedeberg's archives of pharmacology.
2017 Apr; 390(4):435-441. doi:
10.1007/s00210-017-1356-5. [PMID: 28220210] - S Aubrey Stoch, Jeanine Ballard, Christopher Gibson, Filippos Kesisoglou, Rose Witter, Kelem Kassahun, Stefan Zajic, Anish Mehta, Christine Brandquist, Cynthia Dempsey, Daria Stypinski, Marc L Reitman. Coadministration of Rifampin Significantly Reduces Odanacatib Concentrations in Healthy Subjects.
Journal of clinical pharmacology.
2017 01; 57(1):110-117. doi:
10.1002/jcph.780. [PMID: 27321774] - Stefan Zajic, Stefaan Rossenu, David Hreniuk, Filippos Kesisoglou, Jacqueline McCrea, Fang Liu, Li Sun, Rose Witter, Don Gauthier, Roy Helmy, Darrick Joss, Tong Ni, Randall Stoltz, Julie Stone, S Aubrey Stoch. The Absolute Bioavailability and Effect of Food on the Pharmacokinetics of Odanacatib: A Stable-Label i.v./Oral Study in Healthy Postmenopausal Women.
Drug metabolism and disposition: the biological fate of chemicals.
2016 09; 44(9):1450-8. doi:
10.1124/dmd.116.069906. [PMID: 27402726] - Eric S Muise, Alexei A Podtelezhnikov, Maureen Pickarski, Andrey Loboda, Yejun Tan, Guanghui Hu, John R Thomspon, Le T Duong. Effects of Long-Term Odanacatib Treatment on Bone Gene Expression in Ovariectomized Adult Rhesus Monkeys: Differentiation From Alendronate.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
2016 Apr; 31(4):839-51. doi:
10.1002/jbmr.2752. [PMID: 26587671] - Mohd Parvez Khan, Atul Kumar Singh, Abhishek Kumar Singh, Pragya Shrivastava, Mahesh Chandra Tiwari, Geet Kumar Nagar, Himangshu Kousik Bora, Venkitanarayanan Parameswaran, Sabyasachi Sanyal, Jayesh R Bellare, Naibedya Chattopadhyay. Odanacatib Restores Trabecular Bone of Skeletally Mature Female Rabbits With Osteopenia but Induces Brittleness of Cortical Bone: A Comparative Study of the Investigational Drug With PTH, Estrogen, and Alendronate.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
2016 Mar; 31(3):615-29. doi:
10.1002/jbmr.2719. [PMID: 26391310] - Anitha Police, Sandip Gurav, Vinay Dhiman, Mohd Zainuddin, Ravi Kanth Bhamidipati, Sriram Rajagopal, Ramesh Mullangi. Development and validation of an RP-HPLC method for the quantitation of odanacatib in rat and human plasma and its application to a pharmacokinetic study.
Biomedical chromatography : BMC.
2015 Nov; 29(11):1664-9. doi:
10.1002/bmc.3476. [PMID: 25914381] - Kelem Kassahun, Ian McIntosh, Kenneth Koeplinger, Li Sun, Jennifer E Talaty, Deborah L Miller, Russell Dixon, Stefan Zajic, S Aubrey Stoch. Disposition and metabolism of the cathepsin K inhibitor odanacatib in humans.
Drug metabolism and disposition: the biological fate of chemicals.
2014 May; 42(5):818-27. doi:
10.1124/dmd.113.056580. [PMID: 24553380] - Matt S Anderson, Isaias Noel Gendrano, Chengcheng Liu, Steven Jeffers, Chantal Mahon, Anish Mehta, Kate Mostoller, Stefan Zajic, Denise Morris, Jessie Lee, S Aubrey Stoch. Odanacatib, a selective cathepsin K inhibitor, demonstrates comparable pharmacodynamics and pharmacokinetics in older men and postmenopausal women.
The Journal of clinical endocrinology and metabolism.
2014 Feb; 99(2):552-60. doi:
10.1210/jc.2013-1688. [PMID: 24276460] - Sydney Bonnick, Tobias De Villiers, Alberto Odio, Santiago Palacios, Roland Chapurlat, Carolyn DaSilva, Boyd B Scott, Celine Le Bailly De Tilleghem, Albert T Leung, Deborah Gurner. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
The Journal of clinical endocrinology and metabolism.
2013 Dec; 98(12):4727-35. doi:
10.1210/jc.2013-2020. [PMID: 24064689] - S Aubrey Stoch, Rose Witter, David Hreniuk, Chengcheng Liu, Stefan Zajic, Anish Mehta, Christine Brandquist, Cynthia Dempsey, Bruce Degroot, Daria Stypinski, Andrew Denker, John A Wagner. Absence of clinically relevant drug-drug interaction between odanacatib and digoxin after concomitant administration.
International journal of clinical pharmacology and therapeutics.
2013 Aug; 51(8):688-92. doi:
10.5414/cp201864. [PMID: 23782582] - S Aubrey Stoch, Stefan Zajic, Julie A Stone, Deborah L Miller, Lucas van Bortel, Kenneth C Lasseter, Barnali Pramanik, Caroline Cilissen, Qi Liu, Lida Liu, Boyd B Scott, Deborah Panebianco, Yu Ding, Keith Gottesdiener, John A Wagner. Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers.
British journal of clinical pharmacology.
2013 May; 75(5):1240-54. doi:
10.1111/j.1365-2125.2012.04471.x. [PMID: 23013236] - S Aubrey Stoch, Rose Witter, David Hrenuik, Chengcheng Liu, Stefan Zajic, Anish Mehta, Patricia Chandler, Denise Morris, Hongwei Xue, Andrew Denker, John A Wagner. Odanacatib does not influence the single dose pharmacokinetics and pharmacodynamics of warfarin.
Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharmacologie clinique.
2013; 20(3):e312-20. doi:
NULL. [PMID: 24142206] - Patricia J Masarachia, Brenda L Pennypacker, Maureen Pickarski, Kevin R Scott, Gregg A Wesolowski, Susan Y Smith, Rani Samadfam, Jason E Goetzmann, Boyd B Scott, Donald B Kimmel, Le T Duong. Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
2012 Mar; 27(3):509-23. doi:
10.1002/jbmr.1475. [PMID: 22113859] - Li Sun, Sabrina Forni, Michael S Schwartz, Sheila Breidinger, Eric J Woolf. Quantitative determination of odanacatib in human plasma using liquid-liquid extraction followed by liquid chromatography-tandem mass spectrometry analysis.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2012 Feb; 885-886(?):15-23. doi:
10.1016/j.jchromb.2011.12.004. [PMID: 22230741] - Kong Wah Ng. Potential role of odanacatib in the treatment of osteoporosis.
Clinical interventions in aging.
2012; 7(?):235-47. doi:
10.2147/cia.s26729. [PMID: 22866001] - Kelem Kassahun, W Cameron Black, Deborah Nicoll-Griffith, Ian McIntosh, Nathalie Chauret, Stephen Day, Elizabeth Rosenberg, Kenneth Koeplinger. Pharmacokinetics and metabolism in rats, dogs, and monkeys of the cathepsin k inhibitor odanacatib: demethylation of a methylsulfonyl moiety as a major metabolic pathway.
Drug metabolism and disposition: the biological fate of chemicals.
2011 Jun; 39(6):1079-87. doi:
10.1124/dmd.110.037184. [PMID: 21422190] - John A Eisman, Henry G Bone, David J Hosking, Michael R McClung, Ian R Reid, Rene Rizzoli, Heinrich Resch, Nadia Verbruggen, Carolyn M Hustad, Carolyn DaSilva, Romana Petrovic, Arthur C Santora, B Avery Ince, Antonio Lombardi. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
2011 Feb; 26(2):242-51. doi:
10.1002/jbmr.212. [PMID: 20740685] - Anders Bonde Jensen, Christopher Wynne, Guillermo Ramirez, Weili He, Yang Song, Yuliya Berd, Hongwei Wang, Anish Mehta, Antonio Lombardi. The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial.
Clinical breast cancer.
2010 Dec; 10(6):452-8. doi:
10.3816/cbc.2010.n.059. [PMID: 21147688] - S A Stoch, S Zajic, J Stone, D L Miller, K Van Dyck, M J Gutierrez, M De Decker, L Liu, Q Liu, B B Scott, D Panebianco, B Jin, L T Duong, K Gottesdiener, J A Wagner. Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies.
Clinical pharmacology and therapeutics.
2009 Aug; 86(2):175-82. doi:
10.1038/clpt.2009.60. [PMID: 19421185]